1
|
Cazzato G. Cutaneous Manifestations of SARS-CoV-2, Cutaneous Adverse Reactions to Vaccines Anti-SARS-CoV-2 and Clinical/Dermoscopical Findings: Where We Are and Where We Will Go. Vaccines (Basel) 2023; 11:vaccines11010152. [PMID: 36679997 PMCID: PMC9861399 DOI: 10.3390/vaccines11010152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2022] [Revised: 01/04/2023] [Accepted: 01/06/2023] [Indexed: 01/12/2023] Open
Abstract
From the very first months of the pandemic, it became apparent that a variety of skin reactions could occur during COVID-19 disease, starting with 'erythema-pernio'-type lesions, similar to chilblains [...].
Collapse
Affiliation(s)
- Gerardo Cazzato
- Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, 70124 Bari, Italy
| |
Collapse
|
2
|
A Systematic Review of Histopathologic Surveys on Mucocutaneous Biopsies in Patients Developed COVID-19 Vaccine-Related Dermatologic Manifestations. Am J Dermatopathol 2023; 45:1-27. [PMID: 36484603 DOI: 10.1097/dad.0000000000002320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
ABSTRACT Coronavirus 2 is an infectious agent primarily identified as the cause of a pandemic viral pneumonia. With the mass vaccination against this virus, one of the health issues is the safety of currently available vaccines considering their adverse reactions. This systematic review was conducted to assess and summarize all reported data on histopathologic findings associated with mucocutaneous reactions that developed after COVID-19 vaccination for a better pathophysiology interpretation and clinical management of these reactions. A systematic search was performed in PubMed, Web of Science, and Scopus databases as well as Google Scholar engine for relevant English articles published till July 1, 2022. This review includes 131 studies with a total number of 287 cases. Eruptions that underwent a biopsy were mostly described as erythematous maculopapular, papulosquamous, vasculitis-like, lichenoid, or urticarial lesions. Histopathology revealed spongiosis, interstitial, and perivascular lymphohistiocytic infiltration, erythrocyte extravasation, parakeratosis, endothelial inflammation, and the like. Findings were highly consistent with morbilliform erythema, psoriasiform dermatosis, leukocytoclastic vasculitis, and lichenoid or urticarial drug reactions. The majority of these reactions had a mild nature and were primarily observed in patients with underlying health conditions. Microscopic evaluation was also consistent with transient inflammatory changes, and features like neutrophilic infiltrates, subcorneal pustules, and vasculopathy were less frequently reported than what seen in COVID infection. Therefore, dermatologic reactions developing after vaccination in the general population should not hinder a complete vaccination.
Collapse
|
3
|
Bracke C, Miranda C, González S, Casas I, Cardona PJ, Benitez RM, Sopena N, Reynaga EA, Massanella M, Clotet B, Carrillo J, Mateu L, Pedro-Botet ML. Correlation between Clinical and Immunological Variables and Humoral Response to SARS-CoV-2 Vaccination in Adult Patients with Antibody Deficiency Disorders. Pathogens 2022; 11:1364. [PMID: 36422615 PMCID: PMC9696841 DOI: 10.3390/pathogens11111364] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Revised: 11/03/2022] [Accepted: 11/13/2022] [Indexed: 08/05/2023] Open
Abstract
BACKGROUND Prophylactic vaccination has proven to be the most effective strategy to fight the COVID-19 pandemic. METHODS This was a prospective observational cohort study involving 30 predominantly antibody deficiency disorders (ADD)-afflicted adult patients on immunoglobulin replacement therapy vaccinated with three doses of the mRNA-1273 COVID-19 vaccine, and 10 healthy controls. Anti-RBD IgG antibodies were determined in plasma samples collected just before the first dose of mRNA-based COVID-19 vaccine and on weeks 4, 8, 24, and 28 following the first vaccination. Patients were categorized based on the levels of anti-RBD antibodies determined on w8 as non-, low-, and responders. Chi-square and Kruskal-Wallis tests were used to see if any variables correlated with humoral response levels. Any adverse effects of the mRNA-based vaccine were also noted. RESULTS The COVID-19 vaccine was safe and well-tolerated. The humoral response elicited at w8 after vaccination depended on the type of ADD, the type of immunoglobulin deficiency, the presence of granulomatous lymphocytic interstitial lung disease, recent use of immunosuppressive drugs, and the switched memory B cells counts. The third vaccine dose boosted humoral response in previous responders to second dose but seldom in non-responders. CONCLUSIONS The humoral response of patients with predominant ADD depends mostly on the type of immunodeficiency and on the frequency of B and T cell populations.
Collapse
Affiliation(s)
- Carmen Bracke
- Department of Infectious Diseases, Germans Trias i Pujol Hospital, 08916 Badalona, Spain
| | - Cristina Miranda
- Fight AIDS and Infectious Diseases Foundation, 08916 Badalona, Spain
| | - Sandra González
- Fight AIDS and Infectious Diseases Foundation, 08916 Badalona, Spain
| | - Irma Casas
- Department of Preventive Medicine, Germans Trias i Pujol Hospital, 08916 Badalona, Spain
| | - Pere Joan Cardona
- Microbiology Department, Germans Trias i Pujol Hospital, 08916 Badalona, Spain
- Department of Genetics and Microbiology, Autonomous University of Barcelona, 08193 Cerdanyola, Spain
- Respiratory Disease Networking Biomedical Research Center (CIBERes), Carlos III Health Institute, 28029 Madrid, Spain
| | - Rosa Maria Benitez
- Department of Infectious Diseases, Germans Trias i Pujol Hospital, 08916 Badalona, Spain
| | - Nieves Sopena
- Department of Infectious Diseases, Germans Trias i Pujol Hospital, 08916 Badalona, Spain
- Department of Genetics and Microbiology, Autonomous University of Barcelona, 08193 Cerdanyola, Spain
- Respiratory Disease Networking Biomedical Research Center (CIBERes), Carlos III Health Institute, 28029 Madrid, Spain
| | | | - Marta Massanella
- IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Hospital, 08916 Badalona, Spain
- Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, 28029 Madrid, Spain
| | - Bonaventura Clotet
- Department of Infectious Diseases, Germans Trias i Pujol Hospital, 08916 Badalona, Spain
- Department of Genetics and Microbiology, Autonomous University of Barcelona, 08193 Cerdanyola, Spain
- IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Hospital, 08916 Badalona, Spain
- Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, 28029 Madrid, Spain
| | - Jorge Carrillo
- IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Hospital, 08916 Badalona, Spain
- Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, 28029 Madrid, Spain
| | - Lourdes Mateu
- Department of Infectious Diseases, Germans Trias i Pujol Hospital, 08916 Badalona, Spain
- Department of Genetics and Microbiology, Autonomous University of Barcelona, 08193 Cerdanyola, Spain
- Respiratory Disease Networking Biomedical Research Center (CIBERes), Carlos III Health Institute, 28029 Madrid, Spain
| | - Maria Luisa Pedro-Botet
- Department of Infectious Diseases, Germans Trias i Pujol Hospital, 08916 Badalona, Spain
- Department of Genetics and Microbiology, Autonomous University of Barcelona, 08193 Cerdanyola, Spain
- Respiratory Disease Networking Biomedical Research Center (CIBERes), Carlos III Health Institute, 28029 Madrid, Spain
| |
Collapse
|